Zepbound 2.5 MG/0.5 ML pen 0.5ML
Ended Awarded
- Contract number
- SPE2DB25FP60J
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $53,982
Award facts
- Contract value 100% obligated
- $53,981.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $53,981.96 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injectables under a firm fixed-price contract. The award, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location in Conshohocken, PA 19428. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling delivery of a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
Zepbound (tirzepatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used for weight management and diabetes treatment, reflecting the DLA's procurement of contemporary pharmaceutical therapies for military and federal healthcare systems. This delivery order demonstrates AmerisourceBergen Drug Corp's continued capability to fulfill federal medical supply requirements through its established relationship with the DLA, supporting the Defense Health Agency and other government healthcare customers. The non-set-aside designation and firm fixed-price structure are consistent with AmerisourceBergen Drug Corp's existing federal contract portfolio, which encompasses competitively awarded delivery orders spanning diabetes medications, neurological treatments, and specialized medical supplies across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DB25FP60J?
SPE2DB25FP60J was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 19, 2025.
How much is contract SPE2DB25FP60J worth?
The government has obligated $53,982 on SPE2DB25FP60J.
Is contract SPE2DB25FP60J an order under another contract?
Yes. SPE2DB25FP60J is a delivery order under SPE2DB20D1109, an indefinite delivery contract.
Was contract SPE2DB25FP60J competed?
The extent of competition for SPE2DB25FP60J was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award